Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNT327 |
Synonyms | |
Therapy Description |
BNT327 (PM8002) is a bispecific antibody that targets VEGFA and PD-L1 (CD274), which potentially induces antitumor activity (J Clin Oncol 42, no. 16_suppl (May 29, 2024) 5524). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNT327 | PM8002 | PD-L1/PD-1 antibody 121 VEGFA Antibody 4 | BNT327 (PM8002) is a bispecific antibody that targets VEGFA and PD-L1 (CD274), which potentially induces antitumor activity (J Clin Oncol 42, no. 16_suppl (May 29, 2024) 5524). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06449209 | Phase II | BNT327 | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | Recruiting | USA | GBR | AUS | 1 |
NCT06449222 | Phase II | BNT327 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | Recruiting | USA | GBR | AUS | 0 |